NCT06213233

MIVetsCan: Cannabidiol (CBD)-Care Trial

Pragmatic Trial of Cannabidiol to Improve Chronic Pain Symptoms Among Veterans

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 468 (estimated)
• Sponsor: Kevin Boehnke · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period. The study hypotheses: \- CBD would improve overall pain symptoms compared to placebo

Conditions

• Pain, Chronic

Interventions

Type	Name	Description
DRUG	Placebo	Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
DRUG	Cannabidiol	Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

Timeline

• Start date: 2024-02-12
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-01-19
• Last updated: 2025-05-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study